Dr. Reddy's Laboratories (RDY) Financials

$13.52 -0.36 (-2.56%)

Closing price 05/6/2025 03:59 PM Eastern

Extended Trading

$13.32 -0.19 (-1.41%)

As of 05/6/2025 07:59 PM Eastern

Annual Income Statements for Dr. Reddy's Laboratories

This table shows Dr. Reddy's Laboratories' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	3/31/2016	3/31/2017	3/31/2018	3/31/2019	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024
Net Income / (Loss) Attributable to Common Shareholders	302	186	-129,548	272	0.00	0.00	23,568	45,067	55,684
Consolidated Net Income / (Loss)	302	186	9,806	272	0.00	0.00	23,568	45,067	55,684
Net Income / (Loss) Continuing Operations	302	186	-129,548	272	0.00	0.00	23,568	45,067	55,684
Total Pre-Tax Income	410	226	-129,478	325	0.00	0.00	32,298	60,367	71,870
Total Operating Income	447	208	-128,661	302	0.00	0.00	29,476	57,144	67,729
Total Gross Profit	1,393	1,208	76,304	1,206	0.00	0.00	113,840	139,343	163,607
Total Revenue	2,335	2,171	2,226	2,225	0.00	0.00	214,391	245,879	279,164
Operating Revenue	2,335	2,171	2,226	2,225	0.00	0.00	214,391	245,879	279,164
Total Cost of Revenue	942	963	65,724	1,018	0.00	0.00	100,551	106,536	115,557
Operating Cost of Revenue	942	963	65,724	1,018	0.00	0.00	100,551	106,536	115,557
Total Operating Expenses	946	1,000	65,163	904	0.00	0.00	84,364	82,199	95,878
Selling, General & Admin Expense	690	715	46,857	704	0.00	0.00	62,081	68,026	77,201
Research & Development Expense	269	301	18,265	226	0.00	0.00	17,482	19,381	22,873
Exploration Expense	-	-	-	3.04	0.00	0.00	7,562	699	3.00
Other Operating Expenses / (Income)	-13	-16	-12	-28	0.00	0.00	-2,761	-5,907	-4,199
Total Other Income / (Expense), net	-37	18	-817	22	0.00	0.00	2,822	3,223	4,141
Interest Expense	75	12	-	17	0.00	0.00	958	1,428	1,711
Interest & Investment Income	34	24	-	33	0.00	0.00	3,077	4,281	5,705
Other Income / (Expense), net	3.46	5.38	-817	6.33	0.00	0.00	703	370	147
Income Tax Expense	108	40	70	53	0.00	0.00	8,730	15,300	16,186
Basic Earnings per Share	$117.34	$72.24	$59.13	$113.28	$117.63	$103.94	$142.08	$271.43	$334.65
Weighted Average Basic Shares Outstanding	170.55M	-	165.91M	166.07M	166.17M	166.30M	166.43M	166.53M	166.82M
Diluted Earnings per Share	$116.98	$72.09	$0.91	$113.09	$117.40	$103.65	$141.69	$270.85	$334.02
Weighted Average Diluted Shares Outstanding	171.07M	-	165.91M	166.07M	166.17M	166.30M	166.43M	166.53M	166.82M
Weighted Average Basic & Diluted Shares Outstanding	-	-	165.91M	166.07M	166.17M	166.30M	166.43M	166.53M	166.82M

No quarterly income statements for Dr. Reddy's Laboratories are available.

This table details how cash moves in and out of Dr. Reddy's Laboratories' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	3/31/2016	3/31/2017	3/31/2018	3/31/2019	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024
Net Change in Cash & Equivalents	58	-10	-1,294	-5.05	0.00	0.00	-701	-9,359	1,387
Net Cash From Operating Activities	623	-332	18,029	415	0.00	0.00	28,108	58,875	45,433
Net Cash From Continuing Operating Activities	623	332	17,223	415	0.00	0.00	28,108	58,875	45,433
Net Income / (Loss) Continuing Operations	302	186	9,806	272	0.00	0.00	23,568	45,067	55,684
Consolidated Net Income / (Loss)	302	186	9,806	272	0.00	0.00	23,568	45,067	55,684
Depreciation Expense	155	174	11,710	176	0.00	0.00	11,824	12,636	14,841
Non-Cash Adjustments To Reconcile Net Income	274	143	1,784	10	0.00	0.00	18,651	19,741	15,137
Changes in Operating Assets and Liabilities, net	-108	-171	-6,077	-43	0.00	0.00	-25,935	-18,569	-40,229
Net Cash From Investing Activities	-308	-285	-14,883	-112	0.00	0.00	-26,387	-41,373	-40,283
Net Cash From Continuing Investing Activities	-308	-285	-14,883	-112	0.00	0.00	-26,387	-41,373	-40,283
Purchase of Property, Plant & Equipment	-43	-632	-11,043	-121	0.00	0.00	-19,049	-18,866	-27,435
Acquisitions	-120	-0.26	-	0.00	0.00	0.00	-326	0.00	0.00
Purchase of Investments	-1,030	-767	-68,429	-1,136	0.00	0.00	-88,972	-136,171	-145,500
Sale of Property, Plant & Equipment	-180	0.68	139	31	0.00	0.00	3,316	82	1,085
Sale and/or Maturity of Investments	1,065	1,114	64,450	1,114	0.00	0.00	78,644	113,582	131,567
Net Cash From Financing Activities	-257	-57	-4,440	-308	0.00	0.00	-2,422	-26,861	-3,763
Net Cash From Continuing Financing Activities	-257	-57	-4,440	-308	0.00	0.00	-1,971	-26,214	-3,421
Repayment of Debt	-195	-4.67	-449	-243	0.00	0.00	2,175	-21,235	-573
Payment of Dividends	-62	-52	-3,992	-58	0.00	0.00	-4,146	-4,979	-6,648
Issuance of Debt	-	-	-	0.00	0.00	0.00	0.00	0.00	3,800

No quarterly cash flow statements for Dr. Reddy's Laboratories are available.

This table presents Dr. Reddy's Laboratories' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	3/31/2017	3/31/2018	3/31/2019	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024
Total Assets	3,390	3,465	225,427	3,081	0.00	0.00	321,854	387,518
Total Current Assets	1,548	1,684	114,501	1,729	0.00	0.00	204,253	248,049
Cash & Equivalents	60	41	2,228	27	0.00	0.00	5,779	7,107
Short-Term Investments	224	283	22,889	329	0.00	0.00	56,033	74,365
Accounts Receivable	587	624	39,869	667	0.00	0.00	72,485	80,298
Inventories, net	440	447	486	465	0.00	0.00	48,670	63,552
Other Current Assets	185	220	12,536	183	0.00	0.00	20,069	22,560
Plant, Property, & Equipment, net	881	889	54,088	694	0.00	0.00	66,462	76,886
Plant, Property & Equipment, gross	881	889	54,088	694	0.00	0.00	66,462	76,886
Total Noncurrent Assets	960	892	13,113	657	0.00	0.00	48,452	58,865
Long-Term Investments	105	71	3,342	41	0.00	0.00	5,362	5,255
Goodwill	58	61	3,902	53	0.00	0.00	4,245	4,253
Intangible Assets	693	686	642	367	0.00	0.00	30,849	36,951
Noncurrent Deferred & Refundable Income Taxes	86	56	4,168	162	0.00	0.00	7,196	10,774
Other Noncurrent Operating Assets	18	18	1,059	34	0.00	0.00	800	1,632
Total Liabilities & Shareholders' Equity	3,390	3,465	225,427	3,081	0.00	0.00	321,854	387,518
Total Liabilities	1,477	1,523	85,230	1,025	0.00	0.00	90,863	106,968
Total Current Liabilities	1,311	1,070	59,700	966	0.00	0.00	85,845	96,039
Short-Term Debt	673	392	237	275	0.00	0.00	12,194	14,030
Accounts Payable	207	247	14,613	221	0.00	0.00	26,444	30,919
Current Deferred & Payable Income Tax Liabilities	23	23	181	7.60	0.00	0.00	2,144	2,342
Other Current Liabilities	408	408	24,419	463	0.00	0.00	44,928	48,286
Total Noncurrent Liabilities	166	452	25,530	59	0.00	0.00	5,018	10,929
Long-Term Debt	84	385	318	17	0.00	0.00	1,278	5,990
Noncurrent Deferred & Payable Income Tax Liabilities	19	11	610	3.65	0.00	0.00	833	909
Other Noncurrent Operating Liabilities	63	56	42	38	0.00	0.00	2,907	4,030
Total Equity & Noncontrolling Interests	1,913	1,942	140,197	2,056	0.00	0.00	230,991	280,550
Total Preferred & Common Equity	1,913	1,942	139,379	2,056	0.00	0.00	230,611	280,550
Preferred Stock	113	120	8,211	113	0.00	0.00	9,688	10,765
Total Common Equity	1,799	1,823	131,168	1,943	0.00	0.00	220,923	269,785
Common Stock	13	13	12	11	0.00	0.00	833	834
Retained Earnings	1,666	1,749	128,646	1,913	0.00	0.00	215,593	265,257
Treasury Stock	-	0.00	-535	-13	0.00	0.00	-1,269	-991
Other Equity Adjustments	120	61	3,045	32	0.00	0.00	5,766	4,685

No quarterly balance sheets for Dr. Reddy's Laboratories are available.

This table displays calculated financial ratios and metrics derived from Dr. Reddy's Laboratories' official financial filings.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	3/31/2016	3/31/2017	3/31/2018	3/31/2019	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	-7.02%	2.51%	1.98%	-100.00%	0.00%	0.00%	14.69%	13.54%
EBITDA Growth	0.00%	-35.99%	-30,498.26%	31.63%	-100.00%	0.00%	0.00%	67.01%	17.91%
EBIT Growth	0.00%	-52.61%	-60,738.78%	63.75%	-100.00%	0.00%	0.00%	90.58%	18.02%
NOPAT Growth	0.00%	-48.13%	-52,764.97%	102.10%	-100.00%	0.00%	0.00%	98.34%	23.01%
Net Income Growth	0.00%	-38.55%	5,182.16%	80.44%	-100.00%	0.00%	0.00%	91.22%	23.56%
EPS Growth	0.00%	-38.37%	-98.74%	91.68%	3.81%	-11.71%	36.70%	91.16%	23.32%
Operating Cash Flow Growth	0.00%	-153.28%	5,534.76%	49.89%	-100.00%	0.00%	0.00%	109.46%	-22.83%
Free Cash Flow Firm Growth	0.00%	0.00%	-4,169.56%	396.27%	-45.96%	787.05%	1,002.62%	-708.40%	111.90%
Invested Capital Growth	0.00%	0.00%	1.89%	-6.62%	-10.13%	-100.00%	0.00%	0.00%	21.27%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	59.65%	55.65%	3,428.09%	54.23%	0.00%	0.00%	53.10%	56.67%	58.61%
EBITDA Margin	25.92%	17.84%	-5,290.93%	21.78%	0.00%	0.00%	19.59%	28.53%	29.63%
Operating Margin	19.15%	9.59%	-5,780.31%	13.58%	0.00%	0.00%	13.75%	23.24%	24.26%
EBIT Margin	19.29%	9.83%	-5,817.02%	13.86%	0.00%	0.00%	14.08%	23.39%	24.31%
Profit (Net Income) Margin	12.94%	8.55%	440.55%	12.22%	0.00%	0.00%	10.99%	18.33%	19.95%
Tax Burden Percent	73.74%	82.16%	-7.57%	83.75%	0.00%	0.00%	72.97%	74.66%	77.48%
Interest Burden Percent	90.93%	105.82%	100.00%	105.24%	0.00%	0.00%	107.02%	104.96%	105.88%
Effective Tax Rate	26.26%	17.84%	0.00%	16.25%	0.00%	0.00%	27.03%	25.35%	22.52%
Return on Invested Capital (ROIC)	0.00%	14.99%	-3,910.65%	11.25%	0.00%	0.00%	0.00%	49.17%	27.34%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	22.93%	22,685.96%	18.42%	0.00%	0.00%	0.00%	40.80%	22.31%
Return on Net Nonoperating Assets (RNNOA)	0.00%	4.42%	4,419.39%	2.44%	0.00%	0.00%	0.00%	-10.15%	-5.56%
Return on Equity (ROE)	0.00%	19.41%	508.74%	13.69%	0.00%	0.00%	0.00%	39.02%	21.77%
Cash Return on Invested Capital (CROIC)	0.00%	-185.01%	-3,912.52%	18.10%	10.67%	200.00%	0.00%	-150.83%	8.11%
Operating Return on Assets (OROA)	0.00%	6.30%	-3,777.82%	9.17%	0.00%	0.00%	0.00%	35.74%	19.14%
Return on Assets (ROA)	0.00%	5.48%	286.11%	8.08%	0.00%	0.00%	0.00%	28.00%	15.70%
Return on Common Equity (ROCE)	0.00%	18.26%	477.97%	12.87%	0.00%	0.00%	0.00%	37.32%	20.88%
Return on Equity Simple (ROE_SIMPLE)	0.00%	9.71%	504.88%	13.41%	0.00%	0.00%	0.00%	19.54%	19.85%
Net Operating Profit after Tax (NOPAT)	330	171	-90,063	253	0.00	0.00	21,509	42,661	52,476
NOPAT Margin	14.12%	7.88%	-4,046.22%	11.37%	0.00%	0.00%	10.03%	17.35%	18.80%
Net Nonoperating Expense Percent (NNEP)	0.00%	-7.94%	-26,596.61%	-7.16%	0.00%	0.00%	0.00%	8.37%	5.03%
Cost of Revenue to Revenue	40.35%	44.35%	2,952.76%	45.77%	0.00%	0.00%	46.90%	43.33%	41.39%
SG&A Expenses to Revenue	29.54%	32.93%	2,105.13%	31.64%	0.00%	0.00%	28.96%	27.67%	27.65%
R&D to Revenue	11.53%	13.88%	820.59%	10.14%	0.00%	0.00%	8.15%	7.88%	8.19%
Operating Expenses to Revenue	40.50%	46.06%	2,927.55%	40.65%	0.00%	0.00%	39.35%	33.43%	34.34%
Earnings before Interest and Taxes (EBIT)	451	214	-129,478	308	0.00	0.00	30,179	57,514	67,876
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	605	387	-117,768	485	0.00	0.00	42,003	70,150	82,717
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	3.34	3.29	0.00	0.00	0.04	0.05
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	5.26	4.20	0.00	0.00	0.05	0.05
Price to Revenue (P/Rev)	0.00	0.00	0.00	2.86	0.00	0.00	0.04	0.04	0.04
Price to Earnings (P/E)	0.00	0.00	0.00	23.45	0.00	0.00	0.38	0.21	0.22
Dividend Yield	1.44%	0.80%	1.02%	0.76%	0.73%	0.56%	1.25%	1.36%	1.33%
Earnings Yield	0.00%	0.00%	0.00%	4.26%	0.00%	0.00%	261.87%	482.82%	455.87%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	3.06	3.28	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	2.98	0.00	0.00	0.04	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	13.69	0.00	0.00	0.21	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	21.52	0.00	0.00	0.30	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	26.23	0.00	0.00	0.42	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	15.98	0.00	0.00	0.32	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	16.30	29.13	5.03	0.42	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.40	0.40	0.27	0.14	0.00	0.00	0.06	0.07
Long-Term Debt to Equity	0.00	0.04	0.20	0.16	0.01	0.00	0.00	0.01	0.02
Financial Leverage	0.00	0.19	0.19	0.13	0.01	-0.05	0.00	-0.25	-0.25
Leverage Ratio	0.00	1.77	1.78	1.69	1.55	1.50	0.00	1.39	1.39
Compound Leverage Factor	0.00	1.88	1.78	1.78	0.00	0.00	0.00	1.46	1.47
Debt to Total Capital	0.00%	28.36%	28.59%	21.49%	12.44%	0.00%	0.00%	5.51%	6.66%
Short-Term Debt to Total Capital	0.00%	25.21%	14.42%	9.17%	11.70%	0.00%	0.00%	4.99%	4.67%
Long-Term Debt to Total Capital	0.00%	3.15%	14.17%	12.32%	0.74%	0.00%	0.00%	0.52%	1.99%
Preferred Equity to Total Capital	0.00%	4.25%	4.40%	4.60%	4.80%	0.00%	0.00%	3.96%	3.58%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	67.39%	67.02%	73.91%	82.76%	0.00%	0.00%	90.37%	89.76%
Debt to EBITDA	0.00	1.95	-0.01	1.15	0.00	0.00	0.00	0.19	0.24
Net Debt to EBITDA	0.00	0.95	0.00	0.30	0.00	0.00	0.00	-0.77	-0.81
Long-Term Debt to EBITDA	0.00	0.22	0.00	0.66	0.00	0.00	0.00	0.02	0.07
Debt to NOPAT	0.00	4.43	-0.01	2.19	0.00	0.00	0.00	0.32	0.38
Net Debt to NOPAT	0.00	2.15	0.00	0.57	0.00	0.00	0.00	-1.26	-1.27
Long-Term Debt to NOPAT	0.00	0.49	0.00	1.26	0.00	0.00	0.00	0.03	0.11
Altman Z-Score	0.00	0.00	0.00	5.19	4.91	0.00	0.00	2.79	2.80
Noncontrolling Interest Sharing Ratio	0.00%	5.93%	6.05%	6.01%	5.67%	5.48%	0.00%	4.36%	4.07%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	1.18	1.57	1.92	1.79	0.00	0.00	2.38	2.58
Quick Ratio	0.00	0.66	0.89	1.09	1.06	0.00	0.00	1.56	1.68
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-2,110	-90,106	407	220	1,951	21,509	-130,859	15,576
Operating Cash Flow to CapEx	278.87%	-52.55%	165.34%	461.03%	0.00%	0.00%	178.66%	313.43%	172.42%
Free Cash Flow to Firm to Interest Expense	0.00	-175.24	0.00	24.20	0.00	0.00	22.45	-91.64	9.10
Operating Cash Flow to Interest Expense	8.32	-27.55	0.00	24.68	0.00	0.00	29.34	41.23	26.55
Operating Cash Flow Less CapEx to Interest Expense	5.33	-79.97	0.00	19.33	0.00	0.00	12.92	28.07	11.15
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.64	0.65	0.66	0.00	0.00	0.00	1.53	0.79
Accounts Receivable Turnover	0.00	3.70	3.68	3.71	0.00	0.00	0.00	0.00	3.65
Inventory Turnover	0.00	2.19	148.25	2.18	0.00	0.00	0.00	0.00	2.06
Fixed Asset Turnover	0.00	2.46	2.51	2.66	0.00	0.00	0.00	0.00	3.89
Accounts Payable Turnover	0.00	4.65	289.90	4.46	0.00	0.00	0.00	0.00	4.03
Days Sales Outstanding (DSO)	0.00	98.67	99.27	98.47	0.00	0.00	0.00	0.00	99.88
Days Inventory Outstanding (DIO)	0.00	166.73	2.46	167.10	0.00	0.00	0.00	0.00	177.23
Days Payable Outstanding (DPO)	0.00	78.41	1.26	81.90	0.00	0.00	0.00	0.00	90.59
Cash Conversion Cycle (CCC)	0.00	186.99	100.48	183.67	0.00	0.00	0.00	0.00	186.52
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	2,281	2,325	2,171	1,951	0.00	0.00	173,520	210,420
Invested Capital Turnover	0.00	1.90	0.97	0.99	0.00	0.00	0.00	2.83	1.45
Increase / (Decrease) in Invested Capital	0.00	2,281	43	-154	-220	-1,951	0.00	173,520	36,900
Enterprise Value (EV)	0.00	0.00	0.00	6,634	6,406	9,808	9,000	-34,680	-43,727
Market Capitalization	0.00	0.00	0.00	6,372	6,398	9,808	9,000	9,334	12,215
Book Value per Share	$0.00	$10.80	$10.99	$11.50	$11.70	$0.00	$0.00	$1,327.46	$1,620.06
Tangible Book Value per Share	$0.00	$6.29	$6.49	$7.30	$9.17	$0.00	$0.00	$1,116.59	$1,372.63
Total Capital	0.00	2,670	2,720	2,582	2,348	0.00	0.00	244,463	300,570
Total Debt	0.00	757	777	555	292	0.00	0.00	13,472	20,020
Total Long-Term Debt	0.00	84	385	318	17	0.00	0.00	1,278	5,990
Net Debt	0.00	368	382	143	-105	0.00	0.00	-53,702	-66,707
Capital Expenditures (CapEx)	223	631	10,904	90	0.00	0.00	15,733	18,784	26,350
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	626	682	666	682	0.00	0.00	68,790	84,568
Debt-free Net Working Capital (DFNWC)	0.00	910	1,006	1,029	1,038	0.00	0.00	130,602	166,040
Net Working Capital (NWC)	0.00	237	614	792	763	0.00	0.00	118,408	152,010
Net Nonoperating Expense (NNE)	28	-15	-99,869	-19	0.00	0.00	-2,059	-2,406	-3,208
Net Nonoperating Obligations (NNO)	0.00	369	382	143	-105	0.00	0.00	-57,471	-70,130
Total Depreciation and Amortization (D&A)	155	174	11,710	176	0.00	0.00	11,824	12,636	14,841
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	28.85%	30.64%	29.94%	0.00%	0.00%	0.00%	27.98%	30.29%
Debt-free Net Working Capital to Revenue	0.00%	41.92%	45.18%	46.27%	0.00%	0.00%	0.00%	53.12%	59.48%
Net Working Capital to Revenue	0.00%	10.92%	27.57%	35.62%	0.00%	0.00%	0.00%	48.16%	54.45%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.91	$113.28	$117.63	$1.42	$142.08	$271.43	$334.65
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	165.85M	166.07M	166.17M	166.30M	166.43M	166.53M	166.82M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.91	$113.09	$1.56	$1.52	$141.69	$270.85	$334.02
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	166.19M	166.07M	166.17M	166.30M	166.43M	166.53M	166.82M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	165.91M	166.07M	166.17M	166.30M	166.43M	166.53M	166.82M
Normalized Net Operating Profit after Tax (NOPAT)	330	171	-90,026	253	0.00	0.00	21,509	42,661	52,476
Normalized NOPAT Margin	14.12%	7.88%	-4,044.55%	11.37%	0.00%	0.00%	10.03%	17.35%	18.80%
Pre Tax Income Margin	17.54%	10.41%	-5,817.02%	14.59%	0.00%	0.00%	15.07%	24.55%	25.74%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	6.02	17.73	0.00	18.34	0.00	0.00	31.50	40.28	39.67
NOPAT to Interest Expense	4.40	14.20	0.00	15.04	0.00	0.00	22.45	29.87	30.67
EBIT Less CapEx to Interest Expense	3.04	-34.69	0.00	12.98	0.00	0.00	15.08	27.12	24.27
NOPAT Less CapEx to Interest Expense	1.42	-38.22	0.00	9.69	0.00	0.00	6.03	16.72	15.27
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	20.52%	28.16%	40.71%	21.29%	0.00%	0.00%	17.59%	11.05%	11.94%
Augmented Payout Ratio	20.52%	28.16%	40.71%	21.29%	0.00%	0.00%	17.59%	11.05%	11.94%

No quarterly metrics and ratios for Dr. Reddy's Laboratories are available.

Frequently Asked Questions About Dr. Reddy's Laboratories' Financials

When does Dr. Reddy's Laboratories's financial year end?

According to the most recent income statement we have on file, Dr. Reddy's Laboratories' fiscal year ends in March. Their fiscal year 2024 ended on March 31, 2024.

How has Dr. Reddy's Laboratories' net income changed over the last 8 years?

Dr. Reddy's Laboratories' net income appears to be on an upward trend, with a most recent value of $55.68 billion in 2024, rising from $302.08 million in 2016. The previous period was $45.07 billion in 2023. See Dr. Reddy's Laboratories' forecast for analyst expectations on what’s next for the company.

What is Dr. Reddy's Laboratories's operating income?

Dr. Reddy's Laboratories's total operating income in 2024 was $67.73 billion, based on the following breakdown:

Total Gross Profit: $163.61 billion
Total Operating Expenses: $95.88 billion

How has Dr. Reddy's Laboratories revenue changed over the last 8 years?

Over the last 8 years, Dr. Reddy's Laboratories' total revenue changed from $2.34 billion in 2016 to $279.16 billion in 2024, a change of 11,854.5%.

How much debt does Dr. Reddy's Laboratories have?

Dr. Reddy's Laboratories' total liabilities were at $106.97 billion at the end of 2024, a 17.7% increase from 2023, and a 7,142.7% increase since 2017.

How much cash does Dr. Reddy's Laboratories have?

In the past 7 years, Dr. Reddy's Laboratories' cash and equivalents has ranged from $0.00 in 2021 to $7.11 billion in 2024, and is currently $7.11 billion as of their latest financial filing in 2024.

How has Dr. Reddy's Laboratories' book value per share changed over the last 8 years?

Over the last 8 years, Dr. Reddy's Laboratories' book value per share changed from 0.00 in 2016 to 1,620.06 in 2024, a change of 162,005.9%.

Related Companies

This page (NYSE:RDY) was last updated on 5/7/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dr. Reddy's Laboratories (RDY) Financials

Frequently Asked Questions About Dr. Reddy's Laboratories' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dr. Reddy's Laboratories (RDY) Financials

Annual Income Statements for Dr. Reddy's Laboratories

Quarterly Income Statements for Dr. Reddy's Laboratories

Annual Cash Flow Statements for Dr. Reddy's Laboratories

Quarterly Cash Flow Statements for Dr. Reddy's Laboratories

Annual Balance Sheets for Dr. Reddy's Laboratories

Quarterly Balance Sheets for Dr. Reddy's Laboratories

Annual Metrics and Ratios for Dr. Reddy's Laboratories

Quarterly Metrics and Ratios for Dr. Reddy's Laboratories

Frequently Asked Questions About Dr. Reddy's Laboratories' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools